- Home
- WHWK vs CGEN Comparison
WHWK vs CGEN Comparison
Compare WHWK & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WHWK | CGEN |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.4M | 191.1M |
| IPO Year | 2017 | 2001 |
Fundamental Metrics
Financial Performance| Metric | WHWK | CGEN |
|---|---|---|
| Price | $4.73 | $2.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $7.50 | $5.00 |
| AVG Volume (30 Days) | ★ 431.8K | 245.7K |
| Earning Date | 05-06-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 86.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,145,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.60 | $1.30 |
| 52 Week High | $5.50 | $3.24 |
Technical Indicators
Market Signals| Indicator | WHWK | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 62.74 | 50.75 |
| Support Level | $3.79 | $2.20 |
| Resistance Level | $4.84 | $2.54 |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 86.80 | 59.09 |
Price Performance
Historical ComparisonAbout WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.